“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business

Nevro is known for its spinal cord stimulation technology but wants to help a wide range of patients with chronic pain, so it is buying Vyrsa, which offers a complete system for sacroiliac joint fusion. In and interview with Medtech Insight, Nevro CEO Kevin Thornal explained how  Vyrsa supports Nevro's strategy in this growing market.

sacroiliac pain
• Source: Shutterstock

Nevro wants to be more than just a spinal cord stimulation (SCS) company.

Since its founding about 17 years ago, the Redwood City, CA-based company has focused on developing and marketing its high-frequency 10 kHz (HFX) implantable SCS devices to treat chronic pain,...

Nevro Acqures Vyrsa For Up To $75m

On 30 November, Nevro announced that it has signed and closed a deal to pay $40m at closing to acquire Pennsylvania-based Vyrsa.

Nevro also...

More from Deals

More from Business